Treatment and Prognosis of Histiocytic Lymphoma

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and sometimes referred to as histiocytic sarcoma and reticulosarcoma, a subtype of lymphoma.

What is histiocytic lymphoma?

First, some clarification: technically speaking, the term 'histiocytic lymphoma' is outdated and no longer in widespread use, inasmuch as it once referred to a subtype of non-Hodgkin's lymphoma that today we would very likely classify as an anaplastic large cell lymphoma (ALCL).

A histiocyte is a type of macrophage that is found in the body's connective tissue. They work together with lymphocytes to fight foreign pathogens by building antibodies. Because these cells are not white blood cells, but rather make up a type of connective tissue, their classification has traditionally been confusing. This is why you see the term 'sarcoma' in some of the other names for this disease, because a sarcoma is, at its most fundamental, a cancer of any sort of connective tissue.

Treatment and prognosis of histiocytic lymphoma

Because these types of tumors are so rare, there is no consensus about the optimal treatment plan. Generally, doctors will adjust treatment according to how diffuse large cell lymphomas are treated in the same stages as THL.

Prognosis is generally rather poor, not because histiocytic lymphoma is aggressive—in fact, and tends to be indolent—but because they are so rare that little evidence exists to adequately support one treatment over another. Furthermore, these lymphomas quite often are recurrent as well.

Source: The Doctor's Doctor
Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap